Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H Fiero, Sriram Subramaniam, Christy John, Wei Chen, Tiffany K Ricks, Gang Niu, Anthony Fotenos, Min Wang, Kelly Chiang, William F Pierce, Daniel L Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Amna Ibrahim, Paul G Kluetz
On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. The recommended 177Lu-PSMA-617 dose is 7.4 gigabecquerels (GBq; 200 mCi) intravenously every 6 weeks for up to six doses, or until disease progression or unacceptable toxicity...
May 1, 2023: Clinical Cancer Research